Compare · MDLN vs PEN
MDLN vs PEN
Side-by-side comparison of Medline Inc. (MDLN) and Penumbra Inc. (PEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and PEN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $47.84B, about 3.8x PEN ($12.44B).
- Over the past year, MDLN is down 10.6% and PEN is up 23.0% - PEN leads by 33.6 points.
- MDLN has been more active in the news (26 items in the past 4 weeks vs 3 for PEN).
- Both have 25 recent analyst ratings on file.
- Company
- Medline Inc.
- Penumbra Inc.
- Price
- $36.42-1.74%
- $316.20-0.71%
- Market cap
- $47.84B
- $12.44B
- 1M return
- +1.12%
- -3.18%
- 1Y return
- -10.61%
- +23.04%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- 2015
- News (4w)
- 26
- 3
- Recent ratings
- 25
- 25
Penumbra Inc.
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; immersive virtual reality and display system that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Latest MDLN
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P covered exercise/tax liability with 1,889 shares, converted options into 100,000 shares, sold $3,677,115 worth of shares (100,000 units at $36.77) as part of a pre-agreed trading plan and returned 100,000 units of Class B Common Stock to the company, increasing direct ownership by 1,319% to 365,864 units (SEC Form 4)
- Chief Executive Officer Boyle James M covered exercise/tax liability with 2,370 shares, decreasing direct ownership by 7% to 29,369 units (SEC Form 4)
- Director Galanti Richard A was granted 16,392 shares (SEC Form 4)
- Director Sweet Thomas W was granted 17,800 shares (SEC Form 4)
Latest PEN
- Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT
- Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke
- SEC Form SD filed by Penumbra Inc.
- CEO Elsesser Adam gifted 77,000 shares (SEC Form 4)
- SEC Form 425 filed by Penumbra Inc.
- Penumbra Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 10-Q filed by Penumbra Inc.
- Penumbra Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Penumbra Inc.
- SEC Form DEF 14A filed by Penumbra Inc.